Iniciar sesión Regístrese gratis

SinoMab BioScience Ingresos Q/Q

¿Qué es el Ingresos Q/Q de SinoMab BioScience?

El Ingresos Q/Q de SinoMab BioScience Limited es -76.12%

¿Cuál es la definición de Ingresos Q/Q?

El crecimiento de los ingresos trimestrales, año tras año, es el aumento de los ingresos de una empresa en comparación con el compiortamiento en el trimestre correspondiente de un año anterior expresado como un porcentaje.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Ingresos Q/Q de compañías en Sector Health Care en HKSE en comparadas con SinoMab BioScience

¿Qué hace SinoMab BioScience?

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Empresas con ingresos q/q similar a SinoMab BioScience